ERBB2 and triple-negative breast carcinoma: Triple-negative breast cancer (TNBC), which does not express estrogen receptor, progesterone receptor, and HER2 (ERBB2, Erb-B2 receptor), represents an imperative therapeutic need due to its highly invasive nature and relatively poor response to existing treatments (1).